These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 32192503)

  • 21. Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
    Kobayashi K; Toyoda M; Kaneyama N; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Miyakawa M
    J Diabetes Res; 2019; 2019():9415313. PubMed ID: 31781668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B
    J Am Heart Assoc; 2020 Feb; 9(3):e014908. PubMed ID: 31992158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes.
    Gillard P; Schnell O; Groop PH
    Diabetes Res Clin Pract; 2020 Dec; 170():108462. PubMed ID: 32971152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The residual cardiorenal risk in type 2 diabetes.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Feb; 20(1):36. PubMed ID: 33546683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
    Qiu M; Ding LL; Zhang M; Lin JH; Gu JS; Zhou X; Tang YX; Wei XB; Liu SY
    Pharmacol Res; 2020 Nov; 161():105175. PubMed ID: 32860942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Advances in Diabetic Kidney Disease.
    Georgianos PI; Vaios V; Eleftheriadis T; Papachristou E; Liakopoulos V
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand.
    Cavallari I; Maddaloni E
    Diabetes Metab Res Rev; 2019 May; 35(4):e3124. PubMed ID: 30604504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
    Dekkers CCJ; Gansevoort RT; Heerspink HJL
    Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
    Giugliano D; Longo M; Caruso P; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2021 Jul; 23(7):1672-1676. PubMed ID: 33710721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pravastatin in people with diabetes and chronic kidney disease.
    Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
    J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Report from the 5th cardiovascular outcome trial (CVOT) summit.
    Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
    Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 37. Sweet success? SGLT2 inhibitors and diabetes.
    Layton AT
    Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1034-F1035. PubMed ID: 29357429
    [No Abstract]   [Full Text] [Related]  

  • 38. Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?
    Giugliano D; Ceriello A; De Nicola L; Perrone-Filardi P; Cosentino F; Esposito K
    Diabetes Obes Metab; 2020 Feb; 22(2):149-157. PubMed ID: 31495989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
    Sarzani R; Giulietti F; Di Pentima C; Spannella F
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
    Ala M
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.